Brush Clinical Research Ltd. Report issue

For profit Phase 1
Founded: Harrogate United Kingdom (2002)

Organization Overview

First Clinical Trial
2016
NCT02966652
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Brush Clinical Research Limited | Brush Clinical Research Ltd.

Active Ingredients

Drugs in Phase 1 Trials (2)

hydrocortisone (solu-cortef) (3 trials)

testosterone (delatestryl) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adrenal Insufficiency (Phase 1)

Hypogonadism (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 4
  • # of Trial APIs: 2